Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate

• Sutro Biopharma Inc (NASDAQ: STRO) announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta) and interim safety data from exploratory cohort C of advanced ovarian cancer treated at the higher dose of luvelta (5.2mg/kg), along with prophylactic pegfilgrastim.

• Results demonstrated that luvelta provided substantial clinical benefit, with a 37.5% overall response rate (ORR), a median duration of response (median DOR) of 5.5 months, and median progression-free survival (median PFS) of 6.1 months, regardless of starting dose.

• Results also demonstrated that the higher starting dose of 5.2 mg/kg provides greater patient benefit than the lower dose of 4.3mg/kg.

• Consistent with prior luvelta data, the primary adverse event from the dose-expansion cohort was predominantly asymptomatic neutropenia, with no meaningful ocular toxicity signals or complications reported.

• In cohort C, an additional 15 patients with advanced ovarian cancer were enrolled and treated with prophylactic pegfilgrastim on Day 8 after each 5.2 mg/kg administration of luvelta. Initial data on neutropenia and dose delays were available on the first ten patients. This showed that patients in cohort C experienced substantial decreases in neutropenia and potential increases in dose intensity due to decreased dose delays.

• Sutro plans to initiate a Phase 2/3 registration-directed study called REFRaME in the second quarter of 2023.

• Price Action: STRO shares closed at $8.29 on Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.